Effect of surface chemistry of porous silicon microparticles on glucagon-like peptide-1 (GLP-1) loading, release and biological activity

International Journal of Pharmaceutics

Volumn 454, Issue 1, 2013, Pages 67-73

  Huotari, Anne ^a   Xu, Wujun ^a   Mönkäre, Juha ^a,d   Kovalainen, Miia ^a   Herzig, Karl Heinz ^b,c   Lehto, Vesa Pekka ^a   Järvinen, Kristiina ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b UNIVERSITY OF OULU   (Finland)

^c KUOPIO UNIVERSITY HOSPITAL   (Finland)

^d LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Blood glucose levels; GLP 1; In vivo; Mesoporous silicon; Peptide delivery

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; PEPTIDE YY [3-36]; SILICON;

ANIMAL EXPERIMENT; ARTICLE; CHEMISTRY; CONTACT ANGLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG ADSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RELEASE; GLUCOSE BLOOD LEVEL; HYDROPHILICITY; HYDROPHOBICITY; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR SIZE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN STRUCTURE; STATIC ELECTRICITY; SURFACE CHARGE; SURFACE PROPERTY;

EID: 84884134395     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2013.06.063     Document Type: Article

References (28)

1. Amiram, M., Luginbuhl, K.M., Li, X., Feinglos, M.N., Chilkoti, A., 2013. Injectable subcutaneous protease-operated depots of GLP-1 provide extended and tunable glucose control. PNAS 111, 2792-2797.
2. Antosova, Z., Mackova, M., Kral, V., Macek, T., 2009. Therapeutic application of peptides and proteins: parenteral forever? Trends Biotechnol. 27, 628-635.
3. Aulton, M.E., 2007. In: Aulton, M.E. (Ed.), Aulton's Pharmaceutics: The Design and Manufacture of Medicines., 3rd ed. Churchill Livingstone Elsevier, Philadelphia, USA, pp. 63-65.
4. Barrett, E.P., Joyner, L.G., Halenda, P.P., 1951. The determination of pore volume and area distributions in porous substances. I. Computations from nitrogen isotherms. J. Am. Chem. Soc. 73, 373-380.
5. Brunauer, S., Emmett, P., Teller, E., 1938. Adsorption of gases in multimolecular layers. J. Am. Chem. Soc. 60, 309-319.
6. Cao, Y., Gao, W., Jusko, W.J., 2012. Pharmacokinetic/pharmacodynamic modeling of GLP-1 in healthy rats. Pharm. Res. 29, 1078-1086.
7. European Medicines Agency - EMA/318060/2011 EPAR summary for the public. URL: http://www.ema.europa.eu/docs/en GB/document-library/EPAR--- Summary-for-the-public/human/002020/WC500108240.pdf (retrieved 03.03.13).
8. European Medicines Agency - EPAR Scientific discussion-Byetta, URL: European Medicines Agency - EPAR Scientific discussion-Byetta, last updated 14.12.2006. URL: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR - Scientific-Discussion/human/000698/WC500051842.pdf (retrieved 11.10.11).
9. Gao, Z., Tang, Y., Chen, J., Bai, R., Zhang, Q., Hou, Y., Lu, Y., Bai, G., 2009. A novel DPP-IV-resistant analog of glucagon-like peptide-1 (GLP-1): KGLP-1 alone or in combination with long-acting PLGA microspheres. Peptides 30, 1874-1881.
10. Hui, H., Zhao, X., Perfetti, R., 2005. Structure and function studies of glucagon-like peptide-1 (GLP-1): the designing of a novel pharmacological agent for the treatment of diabetes. Diabetes Metab. Res. Rev. 21, 313-331. (Pubitemid 40945953)
11. Jarvis, K.L., Barnes, T.J., Prestidge, C.A., 2012. Surface chemistry of porous silicon and implications for drug encapsulation and delivery applications. Adv. Colloid Interface Sci. 175, 25-38.
12. Jarvis, K.L., Barnes, T.J., Prestidge, C.A., 1431. Thermal oxidation for controlling protein interactions with porous silicon. Langmuir: ACS J. Surf. Colloids 26, 14316-14322.
13. Kaasalainen, M., Mäkilä, E., Riikonen, J., Kovalainen, M., Järvinen, K., Herzig, K.H., Lehto, V.P., Salonen, J., 2012. Effect of isotonic solutions and peptide adsorption on zeta potential of porous silicon nanoparticle drug delivery formulations. Int. J. Pharm. 431, 230-236.
14. Kilpeläinen, M., Mönkäre, J., Vlasova, M.A., Riikonen, J., Lehto, V.P., Salonen, J., Järvinen, K., Herzig, K.H., 2011. Nanostructured porous silicon microparticles enable sustained peptide (melanotan II) delivery. Eur. J. Pharm. Biopharm. 77, 20-25.
15. Kilpeläinen, M., Riikonen, J., Vlasova, M.A., Huotari, A., Lehto, V.P., Salonen, J., Herzig, K.H., Järvinen, K., 2009. In vivo delivery of a peptide, ghrelin antagonist, with mesoporous silicon microparticles. J. Control. Release 137, 166-170.
16. Kovalainen, M., Mönkäre, J., Makila, E., Salonen, J., Lehto, V., Herzig, K., Järvinen, K., 2012. Mesoporous silicon (PSi) for sustained peptide delivery: effect of PSi microparticle surface chemistry on peptide YY3-36 release. Pharm. Res. 29, 837-846.
17. Kovalainen, M., Mönkäre, J., Kaasalainen, M., Riikonen, J., Lehto, V.P., Salonen, J., Herzig, K.H., Järvinen, K., 2013. Development of porous silicon nanocarriers for parenteral peptide delivery. Mol. Pharm. 10, 353-359.
18. Limnell, T., Riikonen, J., Salonen, J., Kaukonen, A.M., Laitinen, L., Hirvonen, J., Lehto, V.P., 2007. Surface chemistry and pore size affect carrier properties of mesoporous silicon microparticles. Int. J. Pharm. 343, 141-147, http://dx.doi.org/10.1016/j.ijpharm.2007.05.010. (Pubitemid 47321019)
19. Mann, A.P., Tanaka, T., Somasunderam, A., Liu, X., Gorenstein, D.G., Ferrari, M., 2011. E-selectin-targeted porous silicon particle for nanoparticle delivery to the bone marrow. Adv. Mater. 23, H278-H282.
20. Mönkäre, J., Riikonen, J., Rauma, E., Salonen, J., Lehto, V., Järvinen, K., 2011. In vitro dissolution methods for hydrophilic and hydrophobic porous silicon micro-particles. Pharmaceutics 3, 315-325.
21. Salonen, J., Kaukonen, A.M., Hirvonen, J., Lehto, V.P., 2008. Mesoporous silicon in drug delivery applications. J. Pharm. Sci. 97, 632-653. (Pubitemid 351293873)
22. Salonen, J., Laitinen, L., Kaukonen, A.M., Tuura, J., Björkqvist, M., Heikkilä, T., Vähä-Heikkilä, K., Hirvonen, J., Lehto, V.P., 2005. Mesoporous silicon microparticles for oral drug delivery: loading and release of five model drugs. J. Control. Release 108, 362-374. (Pubitemid 41608668)
23. Sam, A.H., Troke, R.C., Tan, T.M., Bewick, G.A., 2012. The role of the gut/brain axis in modulating food intake. Neuropharmacology 63, 46-56.
24. Serda, R.E., Mack, A., Pulikkathara, M., Zaske, A.M., Chiappini, C., Fakhoury, J.R., Webb, D., Godin, B., Conyers, J.L., Liu, X.W., Bankson, J.A., Ferrari, M., 2010. Cellular association and assembly of a multistage delivery system. Small 6, 1329-1340.
25. Tanaka, T., Mangala, L.S., Vivas-Mejia, P.E., Nieves-Alicea, R., Mann, A.P., Mora, E., Han, H.D., Shahzad, M.M., Liu, X., Bhavane, R., Gu, J., Fakhoury, J.R., Chiappini, C., Lu, C., Matsuo, K., Godin, B., Stone, R.L., Nick, A.M., Lopez-Berestein, G., Sood, A.K., Ferrari, M., 2010. Sustained small interfering RNA delivery by mesoporous silicon particles. Cancer Res. 70, 3687-3696.
26. Tasciotti, E., Liu, X., Bhavane, R., Plant, K., Leonard, A.D., Price, B.K., Cheng, M.M., Decuzzi, P., Tour, J.M., Robertson, F., Ferrari, M., 2008. Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications. Nat. Nanotechnol. 3, 151-157. (Pubitemid 351355132)
27. Xu, W., Riikonen, J., Lehto, V.P., 2012a. Mesoporous systems for poorly soluble drugs. Int. J. Pharm., http://dx.doi.org/10.1016/j.ijpharm.2012.09.008.
28. Xu, W., Riikonen, J., Nissinen, T., Suvanto, M., Rilla, K., Li, B., Wang, Q., Deng, F., Lehto, V., 2012b. Amine surface modifications and fluorescent labeling of thermally stabilized mesoporous silicon nanoparticles. J. Phys. Chem. C 116, 22307-22314.